Serrhel Adams, MD
Retina Specialist · Springdale, ARNPI 1366474538
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,390 of the $48,055 with a category attached, or 71.6%. Genentech USA, Inc. accounts for 91.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $21,675 and has fallen 94.4% since, to $1,207 in 2025.
Across 121 payments — averaging $397.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$44K
- Astellas Pharma US Inc$2K
- Regeneron Healthcare Solutions, Inc.$303
- Alcon$272
- AbbVie$210
- Boston Scientific$175
- plus $852 from 12 others
Across 37 payments — averaging $5357.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$168K
- AbbVie$14K
- Regeneron$10K
- Eyepoint US, Inc.$7K
What the payments were for
- Consulting fees$9,29019%
- Speaking & faculty fees$34,39072%
- Travel & lodging$9342%
- Food & beverage$3,4417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 45 | $44,117 |
| Astellas Pharma US Inc | 7 | $2,125 |
| Regeneron Healthcare Solutions, Inc. | 15 | $303 |
| Alcon | 4 | $272 |
| AbbVie(2 entities) | 7 | $210 |
| Boston Scientific | 10 | $175 |
| Biogen | 8 | $173 |
| Genentech, Inc. | 3 | $156 |
| Apellis Pharmaceuticals, Inc. | 7 | $143 |
| Novartis | 7 | $116 |
| Carl Zeiss Meditec USA, Inc. | 1 | $96 |
| Coherus Oncology, Inc. | 1 | $34 |
| Sandoz | 1 | $28 |
| Eyepoint US, Inc. | 1 | $26 |
| Amgen | 1 | $23 |
| Alimera Sciences, Inc. | 1 | $22 |
| Dutch Ophthalmic, USA | 1 | $22 |
| Carl Zeiss Meditec, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 91 | $2,319 |
| Difluprednate | 11 | $1,384 |
| Brimonidine Tartrate | 99 | $659 |
| Acetazolamide | 65 | $248 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $27 |
| Diazepam | 25 | $4 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Springdale
- John DellacroceFayetteville$14K
- Cedric PrattLittle Rock$11K
- Alice KennedyConway$5K
- Bradley HughesLittle Rock$4K
- Stephen DavisLittle Rock$3K
- John KingLittle Rock$3K
- Gerald WareLittle Rock$3K
- Muhammad ShamimLittle Rock$2K
- Paul HrubyLittle Rock$1K
- Pedro Soibelmann TetelbomLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.